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background: Menstrual disturbances in female athletes are often explained as a consequence of energy deﬁciency. Oral contraceptive
(OC) treatment may have favorable metabolic effects. We evaluated effects of OCs on diurnal secretions of insulin, insulin-like growth factor
binding protein 1 (IGFBP-1), growth hormone (GH) and cortisol in relation to changes in body composition in athletes with menstrual dis-
turbance compared with regularly menstruating athletes and controls.
methods: Age- and BMI-matched groups of endurance athletes with menstrual disturbance (OAM, n ¼ 9) and regularly cycling athletes
(RM, n ¼ 8) and sedentary controls (CTRL, n ¼ 8) were examined, and hormone levels measured, before and after 8 months of treatment
with a low-dose combined OC (30 mg ethinyl estradiol þ 150 mg levonorgestrel).
results: Before OC treatment, the diurnal proﬁle of insulin was lower (P , 0.01) and levels of IGFBP-1 (P , 0.05) and cortisol (P ,
0.05) were higher in OAM athletes than in CTRL, whereas GH secretion was higher than in RM athletes (P , 0.05). After treatment,
diurnal secretions of these hormones were similar between groups with an increase of IGFBP-1 in the regularly menstruating subjects
only (P , 0.001). OC treatment increased body fat mass in OAM athletes (P , 0.01 versus baseline). The change in total fat mass correlated
positively with pretreatment diurnal levels of GH (rs ¼ 0.67, P , 0.01) and cortisol (rs ¼ 0.64, P , 0.01).
conclusions: OC treatment in endurance athletes with menstrual disturbance increases body fat mass and results in diurnal levels of
insulin, IGFBP-1, GH and cortisol that are comparable to those in regularly menstruating subjects. These results suggest that OCs improve
metabolic balance in OAM athletes.
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Introduction
Menstrual disturbances in female athletes are often explained as a con-
sequence of hypothalamic inhibition owing to energy deﬁciency. The
characteristic hormonal consequences of energy deﬁciency include dis-
ruption of the growth hormone (GH)/insulin-like growth factor (IGF)-I
axis with low levels of IGF-I and insulin, whereas the levels of IGF
binding protein (IGFBP)-1, GH and cortisol are increased (Laughlin
and Yen, 1996; Waters et al., 2001; Rickenlund et al., 2004a).
These changes could be regarded as adaptations to a hypometabolic
state and are also seen in patients with anorexia nervosa (Gianotti
et al., 2002; Stoving et al., 2007). Low IGF-I activity, as well as elevated
cortisol secretion, may lead to inhibition of the hypothalamic–pitu-
itary– gonadal axis, which could explain the decreased LH pulsatility
in amenorrheic athletes (Laughlin and Yen, 1996; De Souza et al.,
2003; Loucks and Thuma, 2003; Rickenlund et al., 2004a).
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treatment results in gain in weight and fat mass in athletes with men-
strual disturbance but not in regularly menstruating athletes and
sedentary controls (Rickenlund et al., 2004b). The largest increase in
fat mass was seen in athletes with the lowest amount of body fat
before treatment (Rickenlund et al., 2004b). On the basis of these
ﬁndings, we hypothesized that in irregularly menstruating athletes,
OC treatment shifts the energy balance toward anabolism. In com-
parison, only small changes in body composition were found in regu-
larly menstruating athletes and sedentary controls. The mechanisms
by which OC treatment increases fat mass in athletes with menstrual
disturbance are not fully established.
Combined estrogen/progestagen OC treatment results in inhibition
of the hypothalamic–pituitary–gonadal axis. OCs also up-regulate the
liver synthesis of several binding proteins (Song et al., 1989; Wiegratz
et al., 2003a). Total levels of cortisol and thyroid hormones will
increase owing to increased levels of their binding proteins, whereas
the free fractions of these hormones remain essentially unchanged
(Wiegratz et al., 2003a, b). Effects of OC treatment on glucoregula-
tory hormones are less explored, and there is little knowledge
about the effects of OCs on IGFBPs (Karlsson et al., 1990; Westwood
et al., 1999). However, both second generation and third generation
OCs have been demonstrated to decrease levels of IGF-I, whereas
IGFBP-3 remains unchanged (Balogh et al., 2000). When investigating
the effects of short-term transdermal estradiol (E2) in weight-stable
amenorrheic athletes, Waters et al. (2003) reported no change in
the levels of GH, IGF-I and IGFBP-1, whereas IGFBP-3 decreased.
However, effects of OC treatment on diurnal hormone levels in ath-
letes have not been studied. We hypothesized that the shift in energy
balance by OCs is reﬂected by changes in diurnal glucoregulatory
hormones.
The aim of the present study was to evaluate the effects of OCs on
the diurnal proﬁles of insulin, IGFBP-1, GH and cortisol in relation to
changes in body composition in endurance athletes with and without
menstrual disturbance and sedentary controls.
Materials and Methods
Subjects
This study included subjects randomly selected from a larger cohort of ath-
letes and sedentary controls (Rickenlund et al., 2003). Female athletes in
endurance sports, such as medium- and long-distance running, marathon,
orienteering, cross-country skiing and triathlon, were recruited from uni-
versities and high schools specializing in sports and at public sports
events and championships in Sweden. Inclusion criteria were healthy, non-
smoking nulliparous women aged 16–35 years with BMI (kg/m
2) 18–24.
Endurance training criteria were deﬁned as a minimum of either 6 h of
aerobic weight-bearing training or a minimum of 70 km of running or
6 h of speciﬁc endurance training weekly. Medical history including eating
behavior and detailed information about the pattern of menstrual
periods during the last year was provided from the subjects and was
based on the athletes’ sport diaries. Amenorrhea was deﬁned as no bleed-
ing for the last 3 months and oligomenorrhea as periods with intervals
exceeding 6 weeks and 5–9 periods the last year. No medications were
allowed. However, intake of minerals/vitamins or nutritional supplements
was accepted.
Inactive women were recruited from universities and high schools and
from the staff at the Karolinska University Hospital. They were screened
using the same criteria as for the athletes, except that the amount of train-
ing was restricted to 1 h of light aerobic training a week. Furthermore, only
regularly menstruating controls were included. All subjects underwent a
general health examination and body weight, height and blood pressure
were recorded. Subjects with menstrual disturbances also underwent a
gynecological examination including ultrasound. The local committee for
medical ethics approved the study protocol and all women gave their
informed consent to participate.
Three groups of women characterized on the basis of endurance train-
ing and menstrual status, and matched for age and BMI were recruited:
athletes with amenorrhea (6) or oligomenorrhea (3) (OAM) athletes, reg-
ularly menstruating (RM) athletes and sedentary regularly menstruating
controls (CTR). A subset of women from these three groups was ran-
domly selected to participate in the present study.
Experimental design
The women were examined before and after a mean period of 8 months
of treatment with a low-dose monophasic, combined OC (30 mg ethinyl
estradiol þ 150 mg levonorgestrel days 1–21 followed by a hormone-
and tablet-free interval days 22–28). Before OC treatment, menstruating
subjects (RM, CTR, oligomenorrheic athletes) were examined in the early
follicular phase (menstrual cycle days 1–5), whereas amenorrheic athletes
were investigated on an arbitrary day. After OC treatment, investigations
were performed during the last week of the active OC treatment cycle.
The examinations started at 7.30 a.m. at the Women’s Health Clinical
Research Unit at the Department of Obstetrics and Gynecology, Karo-
linska University Hospital, Stockholm, Sweden.
Investigation of diurnal proﬁles started at 8.00 a.m. after an over-night
fast. Continuous sampling from an antecubital vein via heparin-coated
PVS tubing (Durascan Medical products ApS, Odense, Denmark) was
carried out by means of a portable, battery-charged excentric pump
(Carmeda, Stockholm, Sweden). Venous blood samples were obtained
every 20 min for 24 h. The withdrawal rate was 8–10 ml/h, and 3m l
was collected in each 20 min period. Blood samples were centrifuged
and sera were stored at 2208C until assayed.
The sampling technique allowed the participants to move freely within
the hospital area. During daytime, the subjects were instructed to
change the reservoir tubes every 20 min, whereas experienced staff
changed the tubes during the night. The period of sleep was recorded
and most subjects slept between 23.00 and 07.00 h. Subjects received
standard meals composed by a nutritionist. Breakfast was served at
08.00, 600 kcal; light snack meal at 10.30, 200 kcal; lunch at 13.00,
750 kcal; light snack meal at 15.30, 200 kcal and dinner at 18.00,
700 kcal and evening meal at 21.00, 250 kcal, all together 2700 kcal with
the nutrient composition of 52% carbohydrate, 17% protein and 32%
fat. The amount of 2700 kcal was calculated based on a moderate
amount of energy for women with a corresponding weight and energy
expenditure. One of the sedentary controls was served vegetarian meals
with equal caloric and nutrient composition. The meals were consumed
within 30 min.
Endurance capacity was assessed at the Department of Physiology and
Pharmacology, Karolinska Institutet. Maximal oxygen uptake (VO2 max)
was determined while the subjects ran on a motor-driven treadmill (Car-
dionics AB, Stockholm, Sweden), using the leveling-off criterion (A ˚strand
and Rodahl, 1986). VO2 max was determined by sampling expired air in
Douglas bags. The oxygen and carbon dioxide contents were measured
with a Beckman analyzer.
Body composition [bone mineral areal density (g/cm
2), lean body mass
(LBM) and fat mass] was determined by dual energy X-ray absorptiometry
86 Rickenlund et al.using the Lunar Model DPX-L equipment (Lunar Radiation, Madison, WI,
USA).
The eating disorder inventory-2 (EDI-2) test was used as screening for
eating disorders (Garner, 1991). This test measures 11 parameters: drive
for thinness, bulimia, body dissatisfaction, ineffectiveness, perfectionism,
interpersonal distrust, interoceptive awareness, maturity fears, asceticism,
impulse regulation and social insecurity. The deﬁned EDI score at risk for
eating disorders, i.e. a cut-off point of 14 on the drive for thinness subscale
(EDI-DT), was used in the evaluation (Garner, 1991). Furthermore, a 24 h
recall of food intake was delivered by all subjects at baseline. The intakes
of energy and nutrients were computed using a food database (Dietist XP
3.0).
Assays
Fasting serum levels of FSH, LH, E2, thyroid-stimulating hormone (TSH),
free thyroxin (fT4) and prolactin were determined by commercial time-
resolved immunoﬂuorometric assays (TR-IFMAs) from PerkinElmer Life-
Sciences, Turku, Finland (Autodelﬁaw). Serum concentrations of testos-
terone and sex hormone-binding globulin (SHBG) were measured by
radioimmunoassay (RIA) in untreated serum, using commercial kits
obtained from Diagnostic Products Corp., Los Angeles, CA, USA
(Coat-a-Countw Testosterone) and Eurodiagnostics AB, MALMO ¨ ,
Sweden (SHBG).
Fasting levels of total IGF-I were determined by RIA after acid ethanol
extraction (Nichols Products Corp.). The levels were expressed in mg/l
of the World Health Organization (WHO) ﬁrst International Reference
Reagent IGF-I 87/518. Free IGF-I was determined using ultraﬁltration by
centrifugation as described previously (Frystyk et al., 1994). The dimeric
complex of IGF-I and IGFBP-1 (binary complex) and IGFBP-2 were deter-
mined by speciﬁc TR-IFMAs as described previously (Frystyk et al., 1995,
2002; Krassas et al., 2003). Fasting levels of corticosteroid-binding globulin
(CBG) were determined using a commercial RIA (Medgenix Diagnostics
SA, Fleurus, Belgium).
Diurnal serum levels of insulin were determined by RIA, using a com-
mercial kit obtained from Pharmacia Diagnostics, Uppsala, Sweden, and
expressed as mIU/l of the WHO International Reference Preparation
66/304. Serum concentrations of IGFBP-1 were determined by RIA as
described by Povoa et al. (1984). The IGFBP-2 and IGFBP-3 cross-
reactivity was less than 0.5% and 0.05%, respectively. Diurnal serum con-
centrations of GH and cortisol were determined by commercial TR-IFMAs
obtained from PerkinElmer LifeSciences (AutoDELFIATM). The concen-
trations of GH were expressed as mg/l of WHO First International GH
Reference Preparation 80/505.
Detection limits and within and between assay coefﬁcients of variation
were for FSH 0.05 U/l, 2% and 3%; for LH 0.05 U/l, 2% and 2%; for E2
13.6 pg/ml, 5% and 8%; for TSH 0.005 mU/l, 3% and 5%; for fT4
1.6 pg/ml, 5% and 4%; for prolactin 0.04 mg/l, 2% and 4%; for testoster-
one 2.8 ng/dl, 6% and 10%; for SHBG 0.005 mg/l, 4% and 8%; for total
IGF-I 6 mg/l, 5% and 7%; for free IGF-I 0.050 mg/l, 15% and 20%; for
IGFBP-2 10 mg/l, 5% and 12%; for the dimeric complex 0.5 mg/l, 5%
and 15%; for CBG 0.3 mg/l, 4% and 6%; for insulin 2 mIU/l, 6% and
6%; for IGFBP-1 3 mg/l, 3.0% and 10.0%; for GH 0.012 mg/l, 2.0% and
3.3%; and for cortisol 0.6 mg/dl, 1.1% and 2.9%, respectively.
Analysis of 24 h proﬁles
Analysis of the diurnal proﬁles of hormones and IGFBP-1 was made using a
computerized pulsatile proﬁle and smoothed baseline diurnal pattern
analysis, applying the Pulsar program developed by Merriam and Watchter
(1982). The program identiﬁes the peaks and the smoothed baseline using
the assay SD as a scale factor. The cut-off parameters G1–G5 for detect-
ing the peaks were set to 2.5, 1.5, 1, 0.75 and 0.5 times the intra-assay SD
for accepting peaks of 1, 2, 3, 4 and 5 points wideness, respectively. Peak
splitting period was set to 1.5. The following four Pulsar parameters were
used for further statistical analysis: area under curve (AUC), 24 h baseline
mean, the number of peaks (peaks/24 h) and mean peak amplitude for
24 h.
Statistical analysis
Normally distributed values are given as the arithmetic mean and SD,
whereas others are given as the median and quartile range (P25–P75).
Differences between groups at baseline were analyzed using a one-way
analysis of variance (ANOVA) followed by Fisher’s least signiﬁcant-
difference post hoc analysis. A two-way ANOVA was used to evaluate
effects of OC treatment within and between groups. In the case of a sig-
niﬁcant interaction (signiﬁcant treatment effect between groups), post hoc
analysis was performed using paired t-test. The distribution for some of
the variables was skewed and therefore these data were log-transformed.
Correlations were assessed using Spearman’s rank-order correlation. A
P-value of ,0.05 was considered statistically signiﬁcant. Software used
was Statistica 6.1 (StatSoft
w Inc., Tulsa, OK, USA).
Results
Baseline characteristics
Baseline characteristics for the study groups are presented in Table I.
Athletes and sedentary controls were comparable as regards age,
menarcheal age, weight and height. There were no differences in
the onset of training, amount of speciﬁc endurance training and
maximal oxygen uptake between the athlete groups. Levels of FSH
were lower in regularly menstruating athletes compared with controls.
The OAM group had signiﬁcantly lower levels of E2 and fT4 than con-
trols and lower levels of prolactin than both regularly menstruating
groups. There were no signiﬁcant differences in hormone values
between the three oligomenorrheic and six amenorrheic athletes in
the OAM group (data not shown).
None of the subjects reported any eating disorder. Furthermore, no
one displayed an EDI-score at risk for eating disorders and the mean
EDI-DT score was comparable between groups (OAM 2.1+3.0, RM
2.3+3.7, CTR 0.4+1.1). The 24 h recall showed no signiﬁcant
differences in total caloric intake at baseline between the three
groups (OAM 2232+414, RM 2543+573, CTR 2155+450 kcal).
However, protein intake was signiﬁcantly lower in the OAM group
compared with the regularly menstruating athletes (84.3+14.5
versus 103.1+17.9 g, P , 0.05) and fat intake tended to be lower
in the OAM athletes compared with the menstruating groups
(53.7+25.0 versus 76.2+22.6 g, P ¼ 0.057).
Effects of OCs on body composition
Data pertaining to body composition are presented in Table II. At
baseline, there was no signiﬁcant difference in BMI between groups.
However, percentage of fat mass was signiﬁcantly lower, whereas
LBM in legs and the ratio of total LBM/fat mass was signiﬁcantly
higher in the OAM group compared with controls. OC treatment
resulted in overall increases in BMI and body weight [both
F(1,22) ¼ 19.0, P , 0.001] but without signiﬁcant differences
between groups. However, there was a signiﬁcant interaction regard-
ing change in fat mass. Thus, oligo-/amenorrheic athletes displayed an
increase in percentage of fat mass with OC, whereas this variable
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no signiﬁcant change in LBM in any group, whereas the ratio of LBM/
fat mass ratio was normalized in the OAM group.
Effects of OCs on fasting levels of IGF-I,
IGFBP-2 and CBG
Fasting levels of IGF-I and its binding proteins are shown in Table III.
There were no signiﬁcant differences between groups in fasting
levels of total and free IGF-I, IGFBP-2 and binary complex (IGF-I þ
IGFBP-1) before or during OC treatment. However, there was an
overall decrease in levels of free IGF-I and IGFBP-2 by OC
[F(1,22) ¼ 8.0, P , 0.01 and F(1,22) ¼ 47.1, P , 0.001, respectively],
whereas levels of total IGF-I were unchanged during treatment. There
was also a tendency to an overall increase in binary complex in the
pooled cohort (F(1,22) ¼ 3.5, P ¼ 0.07].
Fasting levels of CBG before treatment were slightly higher in the
OAM group compared with controls (OAM 52.7+7.3, RM 50.2+
7.9, CTR 44.6+6.5 mg/l, OAM versus CTR, P , 0.05). After treat-
ment, there was a general increase in fasting CBG and mean levels
were similar in the three groups [OAM 107.2+24.5, RM 111.6+
16.7, CTR 110.1+21.3 mg/l, F(1,22) ¼ 248, P , 0.001].
Effects of OCs on diurnal secretion of insulin,
IGFBP-1, GH and cortisol
Diurnal levels of hormones and IGFBP-1 in OAM, RM and CTR are
shown in Table IV. Before OC treatment, OAM displayed signiﬁcantly
lower insulin (AUC and 24 h baseline mean) and higher IGFBP-1 mean
.............................................................................................................................................................................................
Table I Baseline characteristics in OAM athletes, RM athletes and CTR
Groups OAM (n 5 9) RM (n 5 8) CTR (n 5 8) Signiﬁcance
Age (years) 20.3+5.4 20.4+3.1 21.1+4.8 NS
Menarche (age) 13.8+1.4 12.4+1.4 12.9+1.2 NS
Weight (kg) 57.5+6.8 56.0+4.6 54.6+5.8 NS
Height (cm) 171+4 168+4 168+5N S
Onset of training (age) 9.9+2.8 10.8+3.3 — NS
Amount of endurance training (h/w) 7.8+1.3 7.5+1.6 — NS
VO2 max (l/min) 3.3+0.3 3.2+0.2 2.4+0.2 b,c***
FSH (IU/l) 6.3 (4.4–7.2) 5.4 (5.3–5.8) 7.3 (6.4–8.1) c*
LH (IU/l) 5.9 (1.4–8.8) 3.9 (3.0–4.4) 5.9 (5.6–7.6) NS
Estradiol (pg/ml) 31.6+7.0 32.9+14.7 47.5+15.9 b*
TSH (mIU/l) 2.24+0.60 2.42+0.85 2.34+0.84 NS
Free thyroxin (pg/ml) 8.8+1.2 9.1+1.5 11.4+1.5 b*** c**
Prolactin (mg/l) 5.4 (5.3–6.5) 13.0 (11.5–14.0) 12.0 (10.3–15.0) a,b**
Testosterone (ng/dl) 34.3+14.0 31.4+9.1 34.3+11.4 NS
SHBG (mg/l) 3.0+0.8 4.1+0.7 3.8+1.0 NS
Values are expressed as mean+SD or median (P25–P75). VO2 max, maximal oxygen uptake; TSH, thyroid-stimulating hormone; SHBG, sex hormone-binding globulin.
Signiﬁcant differences between groups are indicated *P , 0.05, **P , 0.01 and ***P , 0.001,
aOAM versus RM,
bOAM versus CTR,
cRM versus CTR or NS ¼ not signiﬁcant (one-way
ANOVA followed by Fisher’s post hoc analysis).
............................................... .......................................... ..........................................
.............................................................................................................................................................................................
Table II Body composition before and during treatment with OCs in OAM athletes, RM athletes and CTRs
Groups OAM (n 5 9) RM (n 5 8) CTR (n 5 8)
Before During OC
# Before During OC Before During OC
BMI (kg/m
2) 19.7+1.9 20.5+2.1 19.7+1.5 20.6+1.4 19.3+1.6 19.7+1.4
Fat mass, total (%) 17.7+4.6 b* 21.2+4.5** 21.7+4.8 23.4+4.3 22.7+4.5 23.0+4.2
LBM, total (kg) 45.9+4.1 46.1+5.3 42.5+2.9 42.5+2.8 39.4+3.7 40.0+3.5
LBM, legs (kg) 16.7+2.3 b** 16.0+1.9 15.3+1.2 15.2+1.1 13.7+1.9 14.2+1.5
Total LBM/fat mass ratio 4.73+1.54 b* 3.70+0.98** 3.62+1.15 3.25+1.13 3.33+0.75 3.27+0.76
Values are expressed as mean+SD. Signiﬁcant differences in baseline values between groups are indicated in the ﬁrst OAM column as:
bOAM versus CTR (one-way ANOVA followed by
Fishers post-hoc analysis). Signiﬁcant differences within groups are indicated in the right column, respectively (two-way ANOVA followed by paired t-test in the case of signiﬁcant
interaction), whereas signiﬁcant overall treatment effects are described in the text.
Signiﬁcance levels are *P , 0.05, **P , 0.01 and ***P , 0.001.
#Investigations were performed during the last week of the active OC treatment cycle.
88 Rickenlund et al.peak amplitude than controls. Furthermore, the AUC insulin/IGFBP-1
ratio was signiﬁcantly lower in OAM athletes compared with controls
[0.51 (0.40–1.48) versus 2.49 (0.05–3.10), P , 0.01]. Moreover, pre-
treatment diurnal levels of GH (24 h baseline mean) were signiﬁcantly
higher in OAM than in regularly menstruating athletes, and cortisol
(AUC and 24 h baseline mean) was signiﬁcantly higher in OAM than
in controls.
During OC treatment, there was an overall increase in diurnal
secretion of insulin [AUC: F(1,22) ¼ 15.1, P , 0.001] with no signiﬁ-
cant difference between groups. However, the change in IGFBP-1 dif-
fered between groups with a signiﬁcant increase in the regularly
menstruating subjects (RM and CTR) but not in the OAM athletes
with menstrual disturbance. Diurnal proﬁles of IGFBP-1 before and
during OC treatment in individuals representative of the three
groups are shown in Fig. 1. OC treatment also decreased AUC
insulin/IGFBP-1 ratio in both regularly menstruating groups [RM
1.14 (0.92–1.53) versus 0.75 (0.42–0.94), CTR 2.49 (0.05–3.10)
versus 0.96 (0.84–1.22), P , 0.01, respectively] but not in the
OAM athletes [0.51 (0.40–1.48) versus 0.51 (0.49–0.70)]. Further-
more, there were overall increases in GH [AUC: F(1,22) ¼ 6.6, P ,
0.05, respectively] and cortisol [AUC: F(1,22) ¼ 146, P , 0.001] by
OC treatment with no signiﬁcant change between groups. After treat-
ment, AUC was similar between groups for insulin, IGFBP-1, cortisol
and GH.
Correlations
Pretreatment diurnal baseline mean levels of GH were negatively cor-
related with percentage of total and trunk fat mass (rs ¼ 20.47, P ,
0.05 and rs ¼ 20.45, P , 0.05, respectively). Furthermore, pretreat-
ment GH levels were positively correlated with change in percentage
of total fat mass (rs ¼ 0.67, P , 0.01) and trunk fat mass (rs ¼ 0.49,
P , 0.01) during OC treatment. Diurnal cortisol levels before treat-
ment were also positively correlated with change in the corresponding
fat mass variables (rs ¼ 0.64, P , 0.01 and rs ¼ 0.69, P , 0.01,
respectively). There were no signiﬁcant correlations between insulin
or IGFBP-1 and body composition variables.
Discussion
We have demonstrated that OC treatment in OAM endurance ath-
letes increases body fat mass and results in diurnal levels of insulin,
IGFBP-1, cortisol and GH that are comparable to those in regularly
menstruating athletes and controls. The change in fat mass correlated
with pretreatment diurnal levels of GH and cortisol, which together
with insulin and IGFBP-1 differed signiﬁcantly between oligo-/amenor-
rheic athletes and regularly menstruating subjects at baseline.
Before treatment, OAM athletes had lower diurnal levels of insulin
and higher levels of IGFBP-1 (mean peak amplitude) and cortisol
(AUC and 24 h baseline mean) than regularly menstruating subjects,
as well as lower amount of body fat than controls. The production
of IGFBP-1 is negatively regulated by insulin (Fernqvist-Forbes et al.,
1999) and the low insulin levels in the athletes with menstrual disturb-
ance most likely explain the increased IGFBP-1 secretion. However,
free and total IGF-I was not signiﬁcantly different between OAM ath-
letes and subjects with regular menstruations. Both short-term fasting
(Chen et al., 2005) and anorexia nervosa (Gianotti et al., 2002) have
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Table IV Diurnal levels of hormones and IGFBP-1 before and during treatment with OC in OAM athletes, RM athletes and CTRs
Groups OAM (n 5 9) RM (n 5 8) CTR (n 5 8)
Before During OC Before During OC Before During OC
Insulin (mIU/l)
AUC (mIU/l   24 h) 312 (209–390) b* 401 (372–462) 329 (289–374) 435 (365–490) 449 (381–494) 527 (425–571)
24 h baseline mean 7.0+2.3 b** 8.7+3.2 8.5+2.0 9.0+2.6 11.4+3.0 12.6+2.4
Peaks/24 h 10 (9–12) 9 (8–11) 10.5 (10–13) 9 (8.5–10) 10 (8–11.5) 10.5 (9–11)
Mean peak amplitude 15.4 (12.1–25.3) 22.7 (19.7–24.5) 11.6 (11.1–14.1) 20.6 (17.1–27.6) 17.0 (14.6–26.5) 22.2 (15.6–25.9)
IGFBP-1 (mg/l)
AUC (mg/l   24 h) 520 (230–808) 722 (500–844) 259 (214–387) 654 (454–1250)*** 201 (147–358) 568 (377–702)***
24 h baseline mean 10.4 (4.2–14.0) 12.9 (7.1–22.4) 4.7 (4.0–5.3) 9.4 (7.2–29.4) 3.6 (2.5–6.2) 12.8 (6.8–18.5)
Peaks/24 h 5.8+1.9 5.3+2.1 6.4+1.1 5.6+2.5 8.2+1.8 4.0+1.5 ***
Mean peak amplitude 23.6+13.6 b* 28.4+11.5 16.3+9.2 37.2+22.5** 8.6+3.9 29.3+16.7***
GH (mg/l)
AUC (mg/l   24 h) 50.9 (40.7–60.2) 66.0 (35.2–76.7) 56.9 (39.0–71.3) 56.1 (41.9–71.9) 33.2 (27.0–58.2) 54.2 (34.7–62.3)
24 h baseline mean 0.35 (0.29–0.60) a* 0.72 (0.36–1.07) 0.16 (0.13–0.24) 0.23 (0.18–0.85) 0.15 (0.11–0.22) 0.22 (0.17–0.35)
Peaks/24 h 10.0 (9.0–11.00) 10.0 (9.0–11.0) 9.0 (8.5–9.5) 9.0 (8.5–10.0) 8.0 (7.5–8.5) 9.0 (8.0–12.0)
Mean peak amplitude 3.6 (3.1–4.3) 3.2 (2.8–4.8) 5.4 (3.5–7.1) 4.8 (4.4–5.7) 3.5 (2.9–5.0) 3.9 (3.0–5.4)
Cortisol (mg/dl)
AUC (mg/dl   24 h) 211+41 b* 353+74 173+33 305+56 161+34 293+72
24 h baseline mean 5.2+1.1 b* 9.7+2.4 3.8+1.0 7.8+2.0 3.8+1.1 7.8+2.9
Peaks/24 h 4.8+1.0 3.1+0.6 4.2+0.5 3.5+1.2 5.0+1.5 3.9+2.3
Mean peak amplitude 7.8 (7.2–9.5) 14.6 (12.9–16.6) 8.0 (7.1–9.0) 13.8 (11.7–16.7) 7.1 (5.9–9.0) 14.9 (9.1–17.7)
Values are expressed as mean+SD or median (P25–P75). Signiﬁcant differences between groups before OC treatment are indicated in the ﬁrst OAM column as:
aOAM versus RM and
bOAM versus CTR (one-way ANOVA followed by Fisher’s
posthoc analysis). Signiﬁcant differences within groups are indicated in the right column, respectively (two-way ANOVA followed by paired t-test in the case of signiﬁcant interaction), whereas signiﬁcant overall treatment effects are described in the
text, AUC, area under curve.
Signiﬁcance levels are *P , 0.05, **P , 0.01 and ***P , 0.001.
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.been shown to be associated with signiﬁcantly decreased levels of free
and total IGF-I. In contrast, more modest reduction in caloric intake
appears to have minor or no impact on IGF-I levels (Fontana et al.,
2008). This is in agreement with the ﬁndings in our OAM athletes
who had numerically lower caloric intake and signiﬁcantly lower
protein intake (on average 18%) than the regularly menstruating ath-
letes. Although free IGF-I was lowest in the OAM group, the differ-
ence did not reach signiﬁcance with the limited sample size. The
higher GH secretion in OAM athletes may reﬂect a relative GH resist-
ance as a result of nutritional deﬁcits. This could be explained by the
lower insulin secretion, as insulin is an important regulator of the
hepatic GH receptor density (Leung et al., 2000).
The women in the present study were treated with an OC contain-
ing 30 mg ethinyl estradiol and 150 mg of the androgenic progestagen,
levonorgestrel, for a mean period of 7 months. It has been shown
from studies of normal subjects of different ages that oral adminis-
tration of estrogens and androgens have partly opposite effects on
the GH–IGF– IGFBP axis (Heald et al., 2005; Rooman et al., 2005;
Veldhuis et al., 2005). Oral estrogens impair the metabolic actions
of GH in the liver causing a fall in circulating-free IGF-I, which via
Figure 1 Diurnal proﬁles of IGFBP-1 before and during treatment with OC (30 mg ethinyl etradiol þ 150 mg levonorgestrel) in three representative
study individuals: one athlete with OAM, one athlete with RM, and one regularly menstruating CTR.
Oral contraceptives and hormone secretion in athletes 91negative feedback regulation may increase GH secretion (Rooman
et al., 2005; Veldhuis et al., 2005). This fall of IGF-I appears to be
caused both by depression of post-receptor GH signaling in the hep-
atocytes and by increase in circulating GH-binding protein, reducing
the availability of GH to the receptor (Leung et al., 2004). Further-
more, IGFBP-1 is stimulated and IGFBP-2 is suppressed by oral estro-
gens. Androgens on the other hand have been reported to stimulate
free IGF-I and have no effect on IGFBP-1 and -2 (Rooman et al., 2005).
It has been shown that the decrease in IGF-I during administration of
combined OCs containing the androgenic progesterone levonorges-
trel is lower than with the anti-androgenic dienogest (Balogh et al.,
2000). In the present study, we found no change in fasting levels of
total IGF-I but a general decrease in free IGF-I with a non-signiﬁcant
increase in the IGF-I–IGFBP-1 binary complex as well as a decrease
in IGFBP-2. Thus, the effects of ethinyl estradiol may have been
partly obviated by levonorgestrel.
Diurnal levels of insulin (AUC) increased during OC treatment in all
groups. This is most likely a result of decreased insulin sensitivity
known to occur during OC treatment (Crook and Godsland, 1998).
Regularly menstruating athletes and sedentary controls had a substan-
tial increase in IGFBP-1 (AUC and mean peak amplitude) and a
decrease in the ratio of insulin/IGFBP-1. In contrast, this ratio was
unchanged in athletes with menstrual disturbance and levels of
IGFBP-1 displayed unchanged diurnal variations. Furthermore, there
were general increases of GH (AUC), probably attributed to the
decrease in free IGF-I. Diurnal levels of cortisol (AUC) were also
increased in the three groups, which was most likely the result of a
concomitant increase in CBG since free cortisol does not increase
during OC treatment (Simunkova et al., 2008). The signiﬁcant differ-
ences between groups before OC treatment in insulin (AUC),
IGFBP-1 (mean peak amplitude) and cortisol (AUC and 24 h baseline
mean) were abolished after treatment. OCs signiﬁcantly increased fat
mass in athletes with oligo-/amenorrhea but not in regularly menstru-
ating athletes and sedentary controls. The increase in body fat was
positively related to diurnal levels of cortisol and GH before treat-
ment. Thus, high pretreatment levels of GH and cortisol indicate
reduced energy stores, which can be reversed by OC treatment.
The precise mechanisms for the OC-associated increase in weight
and fat mass in the athletes with menstrual disturbance but not in reg-
ularly menstruating subject are unknown. Sex steroids may interfere
with appetite and metabolic functions. E2 is known to inhibit feeding
in animals and to increase the activity of the cholecystokinin (CCK)
satiation signaling pathway (Geary, 2001), whereas high-dose proges-
tagens are appetite stimulating (Maltoni et al., 2001). We have pre-
viously demonstrated a suppressed secretion of the satiety peptide
CCK during OC treatment related to an increase in body fat in
young women (Hirschberg et al., 1996). Thus, some women may
experience changes in appetite and weight by OC treatment, although
studies so far in general have failed to show any effect on body weight
and body composition (Franchini et al., 1995; Reubinoff et al., 1995;
Lloyd et al., 2002; De Melo et al., 2004). Despite extensive clinical
experience of OC treatment, effects on appetite and metabolism
still remain to be explored.
In anorexia nervosa and other conditions with severe undernutri-
tion, OC treatment has not been shown to have signiﬁcant effect
on weight recovery (Miller et al., 2006). However, in the present
study, none of the subjects suffered from any eating disorder that
would restrain food intake. Moreover, similar physical activity was
reported during the study period. It is therefore possible that the
OC treatment might have brought about a change in appetite and sub-
sequently increased food intake. However, an alternative explanation
is that OC treatment induces metabolic changes, such as decreased fat
oxidation, resulting in increased fat mass as a source for energy
utilization. Subjects with reduced energy stores may be more prone
to gain weight than those with adequate nutrition.
A limitation with the present study was the relatively small sample
size. However, the study comprised a well-deﬁned cohort of female
endurance athletes. The strength of the study was the prospective
design by which the subjects were rigorously studied during
8 months of OC treatment.
In summary, this study demonstrates that OC treatment in endur-
ance athletes with menstrual disturbance increases body fat mass and
results in diurnal levels of insulin, IGFBP-1, GH and cortisol that are
comparable to those in regularly menstruating subjects. These
results suggest that OCs improve metabolic balance in OAM athletes.
The treatment could therefore be beneﬁcial for athletes with oligo-/
amenorrhea resulting from hypothalamic inhibition. However, ade-
quate nutrition should be encouraged as the ﬁrst line of strategy.
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